Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.001 |
mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.002 |
mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.002 |
mRNA | FK866 | GDSC1000 | pan-cancer | AAC | 0.094 | 0.002 |
mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.092 | 0.002 |
mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.096 | 0.003 |
mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.087 | 0.003 |